chrX-17022254-G-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_004726.3(REPS2):c.529G>A(p.Asp177Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000273 in 1,208,339 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 11 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000018 ( 0 hom., 0 hem., cov: 24)
Exomes 𝑓: 0.000028 ( 0 hom. 11 hem. )
Consequence
REPS2
NM_004726.3 missense
NM_004726.3 missense
Scores
2
4
11
Clinical Significance
Conservation
PhyloP100: 4.46
Genes affected
REPS2 (HGNC:9963): (RALBP1 associated Eps domain containing 2) The product of this gene is part of a protein complex that regulates the endocytosis of growth factor receptors. The encoded protein directly interacts with a GTPase activating protein that functions downstream of the small G protein Ral. Its expression can negatively affect receptor internalization and inhibit growth factor signaling. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.16002092).
BS2
High Hemizygotes in GnomAdExome4 at 11 gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
REPS2 | NM_004726.3 | c.529G>A | p.Asp177Asn | missense_variant | 3/18 | ENST00000357277.8 | NP_004717.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
REPS2 | ENST00000357277.8 | c.529G>A | p.Asp177Asn | missense_variant | 3/18 | 1 | NM_004726.3 | ENSP00000349824.3 | ||
REPS2 | ENST00000303843.7 | c.529G>A | p.Asp177Asn | missense_variant | 3/18 | 1 | ENSP00000306033.7 | |||
REPS2 | ENST00000481792.1 | n.321G>A | non_coding_transcript_exon_variant | 3/3 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000179 AC: 2AN: 112002Hom.: 0 Cov.: 24 AF XY: 0.00 AC XY: 0AN XY: 34176
GnomAD3 genomes
AF:
AC:
2
AN:
112002
Hom.:
Cov.:
24
AF XY:
AC XY:
0
AN XY:
34176
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000275 AC: 5AN: 182011Hom.: 0 AF XY: 0.0000600 AC XY: 4AN XY: 66629
GnomAD3 exomes
AF:
AC:
5
AN:
182011
Hom.:
AF XY:
AC XY:
4
AN XY:
66629
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000283 AC: 31AN: 1096282Hom.: 0 Cov.: 28 AF XY: 0.0000304 AC XY: 11AN XY: 361726
GnomAD4 exome
AF:
AC:
31
AN:
1096282
Hom.:
Cov.:
28
AF XY:
AC XY:
11
AN XY:
361726
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000178 AC: 2AN: 112057Hom.: 0 Cov.: 24 AF XY: 0.00 AC XY: 0AN XY: 34241
GnomAD4 genome
AF:
AC:
2
AN:
112057
Hom.:
Cov.:
24
AF XY:
AC XY:
0
AN XY:
34241
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
4
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 05, 2023 | The c.529G>A (p.D177N) alteration is located in exon 3 (coding exon 3) of the REPS2 gene. This alteration results from a G to A substitution at nucleotide position 529, causing the aspartic acid (D) at amino acid position 177 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Benign
T;.
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N
REVEL
Benign
Sift
Benign
D;D
Sift4G
Benign
T;T
Polyphen
P;D
Vest4
MutPred
Loss of phosphorylation at S172 (P = 0.1173);Loss of phosphorylation at S172 (P = 0.1173);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at